Overview

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients

Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label phase II study with a safety lead-in phase.
Phase:
Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin
Treatments:
Antibodies, Monoclonal
BB 1101
Bortezomib
Cyclophosphamide
Dexamethasone
Dexamethasone acetate